PE20141358A1 - Polimorfos de inhibidores de cinasas - Google Patents

Polimorfos de inhibidores de cinasas

Info

Publication number
PE20141358A1
PE20141358A1 PE2014000191A PE2014000191A PE20141358A1 PE 20141358 A1 PE20141358 A1 PE 20141358A1 PE 2014000191 A PE2014000191 A PE 2014000191A PE 2014000191 A PE2014000191 A PE 2014000191A PE 20141358 A1 PE20141358 A1 PE 20141358A1
Authority
PE
Peru
Prior art keywords
compound
formula
polymorph
polymorphes
kinase inhibitors
Prior art date
Application number
PE2014000191A
Other languages
English (en)
Spanish (es)
Inventor
Pingda Ren
Michael Martin
Original Assignee
Intellikine Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47669006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intellikine Llc filed Critical Intellikine Llc
Publication of PE20141358A1 publication Critical patent/PE20141358A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2014000191A 2011-08-11 2012-08-10 Polimorfos de inhibidores de cinasas PE20141358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161522624P 2011-08-11 2011-08-11

Publications (1)

Publication Number Publication Date
PE20141358A1 true PE20141358A1 (es) 2014-10-12

Family

ID=47669006

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000191A PE20141358A1 (es) 2011-08-11 2012-08-10 Polimorfos de inhibidores de cinasas

Country Status (25)

Country Link
US (1) US20150065524A1 (enExample)
EP (1) EP2741749A4 (enExample)
JP (1) JP2014521726A (enExample)
KR (1) KR20140079368A (enExample)
CN (1) CN103957918A (enExample)
AU (1) AU2012294202B2 (enExample)
BR (1) BR112014003214A2 (enExample)
CA (1) CA2844742A1 (enExample)
CL (1) CL2014000343A1 (enExample)
CO (1) CO6960542A2 (enExample)
CR (1) CR20140082A (enExample)
DO (1) DOP2014000027A (enExample)
EA (1) EA027970B1 (enExample)
EC (1) ECSP14013236A (enExample)
HK (1) HK1199203A1 (enExample)
IL (1) IL230850A0 (enExample)
MX (1) MX2014001662A (enExample)
MY (1) MY186267A (enExample)
PE (1) PE20141358A1 (enExample)
PH (1) PH12014500331A1 (enExample)
RU (1) RU2636588C2 (enExample)
SG (2) SG10201606288TA (enExample)
TN (1) TN2014000063A1 (enExample)
WO (1) WO2013023184A1 (enExample)
ZA (1) ZA201401211B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747747B (zh) 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
BRPI0922611A2 (pt) 2008-12-17 2018-11-06 Angiochem Inc inibidores de metaloproteína de matriz de membrana tipo 1 e usos dos mesmos
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
CN106924741A (zh) * 2011-11-08 2017-07-07 因特利凯有限责任公司 使用多种药剂的治疗方案
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途
CN105899232A (zh) 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
AU2014366047B2 (en) 2013-12-19 2021-03-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
HRP20240874T1 (hr) 2014-04-07 2024-10-11 Novartis Ag Liječenje raka korištenjem kimernog antigenskog receptora anti-cd19
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー GFRα−4キメラ抗原受容体を用いる癌の治療
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
EP3967709A1 (en) 2014-09-17 2022-03-16 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10774388B2 (en) 2014-10-08 2020-09-15 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016205367A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
ES2636646B1 (es) * 2016-04-05 2018-08-03 Universidade De Santiago De Compostela NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
ES2837396T3 (es) 2016-11-23 2021-06-30 Bayer Cropscience Ag Derivados de 2-[3-(alquilsulfonil)-2H-indazol-2-il]-3H-imidazo[4,5-b]piridina y compuestos similares como pesticidas
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
BR112020013794B1 (pt) * 2018-01-09 2023-05-02 Halcyon Labs Private Limited Processo para a preparação de crisaborola de fórmula (i), compostos, uso de um composto de fórmula (iv), (iii) ou (ii), processo para a preparação de crisaborola altamente pura e sal
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
NZ612909A (en) * 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones

Also Published As

Publication number Publication date
CL2014000343A1 (es) 2014-10-17
BR112014003214A2 (pt) 2017-03-14
MY186267A (en) 2021-07-01
WO2013023184A1 (en) 2013-02-14
PH12014500331A1 (en) 2014-03-31
MX2014001662A (es) 2014-08-26
CN103957918A (zh) 2014-07-30
DOP2014000027A (es) 2014-07-15
AU2012294202A1 (en) 2014-03-06
ZA201401211B (en) 2015-12-23
RU2014109023A (ru) 2015-09-20
SG2014009492A (en) 2014-09-26
NZ622208A (en) 2016-04-29
EP2741749A1 (en) 2014-06-18
ECSP14013236A (es) 2014-06-30
IL230850A0 (en) 2014-03-31
JP2014521726A (ja) 2014-08-28
KR20140079368A (ko) 2014-06-26
SG10201606288TA (en) 2016-09-29
TN2014000063A1 (en) 2015-07-01
CR20140082A (es) 2014-06-03
CO6960542A2 (es) 2014-05-30
US20150065524A1 (en) 2015-03-05
RU2636588C2 (ru) 2017-11-24
EA027970B1 (ru) 2017-09-29
AU2012294202B2 (en) 2017-02-23
CA2844742A1 (en) 2013-02-14
EP2741749A4 (en) 2015-04-15
HK1199203A1 (en) 2015-06-26
EA201490446A1 (ru) 2014-05-30

Similar Documents

Publication Publication Date Title
PE20141358A1 (es) Polimorfos de inhibidores de cinasas
AR131761A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CR20120268A (es) Método para reducir el estrés por temperatura de plantas
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
NI201200017A (es) Formulación farmacéutica
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
EA201100037A1 (ru) Органические соединения
CR20130534A (es) Nuevos derivados de imidazol útiles para el tratamiento de artritis
MX373196B (es) Inhibidores de histona desacetilasa novedosos.
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
UA108378C2 (uk) Спосіб одержання плеуромутилінів
CR20130177A (es) Método para reducir estrés hídrico en plantas
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
CL2012001461A1 (es) Compuestos derivados de difenil-pirazolopiridinas, moduladores del receptor nuclear nurr-1; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades inflamatorias, osteoporosis, cáncer, entre otras.
CL2018000241A1 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il) propanoico sustituido.
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
EA201391371A1 (ru) Фармацевтическая композиция ситаглиптина
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
CU24366B1 (es) Compuestos que poseen un anillo que contiene nitrógeno salicílico unido a un grupo heteroarilo bicíclico útiles como inhibidores rorc2

Legal Events

Date Code Title Description
FC Refusal